Nurix Therapeutics (NRIX)

Nurix’s discovery engine combines expertise in E3 ligases, medicinal chemistry, immunology, and computational tools, including artificial intelligence-supported design. The platform is intended to identify molecules that can bring disease-related proteins into proximity with the cell’s degradation machinery, causing those proteins to be broken down. This gives the company a position in one of the more closely watched areas of modern drug discovery.

Its pipeline includes bexobrutideg, also known as NX-5948, a Bruton's tyrosine kinase degrader being studied for certain B-cell malignancies and immune-mediated conditions. Zelebrudomide, or NX-2127, is another degrader candidate aimed at BTK and related immune pathways. Nurix is also advancing NX-1607, an immuno-oncology candidate focused on CBL-B, as well as degrader programs against cancer targets such as BRAF.

As a development-stage company, Nurix’s value depends heavily on clinical data, regulatory progress, financing capacity, and the competitiveness of its science. It has also used collaborations with larger pharmaceutical companies to extend the reach of its platform while maintaining internal programs that could become wholly owned therapeutic assets.